← Search another drug
PatientPulse · by PatientPartner
Remicade infliximab
High confidence
~58 public patient conversations and reviews analyzed (blogs, forum threads, review pages, and news articles)
Executive intelligence
The signal that moves starts & adherence
42%Positive sentiment in discussion
212,272FDA adverse-event reports
88%Flagged serious
63%Reports name female patients
The single biggest commercial risk is not efficacy loss but insurance-forced biosimilar switching: patients who feel informed and supported stay; those switched without counseling discontinue at high rates and often attribute subjective worsening to the switch even when biomarkers hold steady.
- Remicade delivers fast, dramatic remission that patients describe as life-restoring, making it a high-loyalty brand despite a demanding IV infusion schedule every 6-8 weeks.
- Infusion reactions and antibody development are the dominant fear signals; even a single anaphylaxis event triggers intense discussion about permanent discontinuation and switching to Humira or Entyvio.
- Cost and insurance friction, including insurance-forced biosimilar switches, generate the loudest negative sentiment and are the leading driver of treatment disruption outside of clinical failure.
- A meaningful nocebo effect surrounds biosimilar switching: patients switched without adequate counseling report subjective deterioration even when drug levels and inflammatory markers remain stable, representing a recoverable adherence leak.